Hunter Syndrome is also called Mucopolysaccharidosis type II (MPS II). It is a disease, which affects several different parts of the body and usually affects males. It is a progressive disorder, but the rate of progression varies among affected persons. It is a rare, X-linked disorder caused by a deficiency of the lysosomal enzyme iduronate-2-sulfatase, which plays a significant role in catabolism glycosaminoglycans (GAG).
There are two types of MPS II, which is known as severe and mild types. While both types affect various organs and tissues, people with severe MPS II also face a decline in intellectual function and a more rapid disease progression. Individuals with severe form start to lose necessary functional skills (developmentally regress) between 6 and 8 aged children. The life expectancy of these people is 10–20 years. The individuals with mild MPS II also have a less lifespan, but they typically live into adulthood, and their intelligence is not affected. Heart disease and airway obstruction are significant causes of death in people with both types of MPS II.
Hunter Syndrome Epidemiological Segmentation
The Epidemiological Segmentation of Hunter Syndrome in 7MM from 2017 to 2030 is segmented as:-
- Total Prevalent Cases of Hunter Syndrome
- Severity Specific Prevalence of Hunter Syndrome [Mild and Severe Form]
- Diagnosed and Treatable Population of Hunter Syndrome
Hunter Syndrome Epidemiology
The diagnosed prevalence of Hunter syndrome in 7MM in 2020 was 1,166
The Diagnosed Prevalence of Hunter syndrome in the United States in 2020 was 515
Hunter Syndrome Market Size is expected to increase at a CAGR of 7.5% for the Study Period (2017-2030) in the 7MM.
Hunter Syndrome Key Players
The key players in the Hunter Syndrome market are
- JCR Pharmaceuticals
- GC Pharma
- Denali Therapeutics
- Sangamo Therapeutics
And many others.